BRIACELL THERAPEUTICS CORP C/WTS 15/01/2031 (TO PUR  COM)

Edesa Biotech

Rich Sparkle

Brand Engagement Network

Clarivate

Ten-League

Palvella Therapeutics

Biorestorative Therapies

Founder

Larimar Therapeutics

Gain Therapeutics

ARKG

<p>BriaCell Therapeutics Corp., a clinical-stage biotechnology company listed on both Nasdaq (BCTX, BCTXW, BCTXZ, BCTXL) and TSX (BCT), has recently shared new images showcasing the successful treatment of metastatic breast cancer in patients with lesions in the eye, brain, liver, and spine. The company's Phase 2 study includes survival data on these patients and others, which has been previously disclosed. This development demonstrates the potential of BriaCell's immunotherapies to revolutionize cancer care.</p>

Unusual Whales

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

iShares Global Healthcare

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

VanEck Biotech ETF

BriaCell Therapeutics

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Health Care Select Sector SPDR

VG Health

BRIACELL THERAPEUTICS CORP C/WTS (TO PUR COM)

BRIACELL THERAPEUTICS CORP C/WTS 26/02/2026(TO PUR COM)

BriaCell shows tumors regression in metastasized cancer patients with liver, brain involvement. Study details included.

BRIACELL THERAPEUTICS CORP C/WTS 15/01/2031 (TO PUR COM)(BCTXL.US)

BriaCell shows tumors regression in metastasized cancer patients with liver, brain involvement. Study details included.